Dr. Stephanie Lin, MD

Dr. Lin practices at Endoscopy Center of Marin - HOPD in Greenbrae, California.

Dr. Lin's NPI, 1598839052, was assigned on November 17, 2006. Dr. Lin graduated from Stanford University School Of Medicine in 1997. Dr. Lin holds California license A68739.

Dr. Lin's primary practice is Endoscopy Center of Marin - HOPD, at 1100 S Eliseo Dr, Greenbrae, CA 94904.

Dr. Lin's primary practice is Endoscopy Center of Marin - HOPD in Greenbrae, California. Dr. Lin is also affiliated with MarinHealth Medical Center. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Lin to 3 more hospitals, 4 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 7 sites in all. Vendor and product names are available with a free account.

Vascular surgery is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 2086S0129X. Dr. Lin is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Lin's licenses on file in 2 states: California and New York.

Dmand AI lists amputation, arterial blot clot /embolism, blood vessel access for dialysis, carotid revascularization, chronic skin ulcer, deep vein thrombosis (DVT), heart device and aorta surgery and leg revascularization among the conditions Dr. Lin treats.

CMS data shows 1,583 Medicare services from Dr. Lin across 26 procedure codes in 2024, for 854 Medicare patients. Medicare paid $79,763 for them.

CMS counts 854 Medicare patients who saw Dr. Lin in 2024. The largest group is 75 to 84, with 384 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 75, with 48% women.

In 2024, Dr. Lin wrote 142 Medicare Part D claims for 49 patients. 61% of them were for generic drugs. CMS names the drug for 106 of them, across 4 drugs with 11 or more claims each, at $48,475 in total drug cost. In 2023, CMS named 119 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. CMS lists Dr. Lin as offering telehealth. CMS counts 13 procedures of leg revascularization (restoring blood flow) by Dr. Lin, more than 68% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 20 papers to Dr. Lin in 2006. The most frequent topics are Stents, Angioplasty, Balloon and Blood Vessel Prosthesis Implantation. Dr. Lin has published most often in J Vasc Surg. Dr. Lin's most frequent co-authors are Peter L. Faries, MD, Rabih A. Chaer and Rajeev Dayal, MD.

CMS Open Payments shows 209 general payments to Dr. Lin from 36 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 41% of the total. Boston Scientific Corporation paid the most, $8,259.

Dmand AI lists 2 awards for Dr. Lin, most recently CMS Stage 1 EHR in 2013.

Dr. Lin graduated from Stanford University School Of Medicine in 1997. Dr. Lin is a member of ACS.

Dr. Lin is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.